Allergan CEO Saunders to oversee 'Pfizergan' commercial ops; Novartis picks up 2 Cosentyx nods in Europe;

> Allergan ($AGN) CEO Brent Saunders will be responsible for the oversight of all Pfizer ($PFE) and Allergan's combined commercial businesses under the new deal agreement between the two. Release

> Novartis ($NVS) has won European approval for Cosentyx in ankylosing spondylitis and psoriatic arthritis. Report

> AstraZeneca ($AZN) has agreed to sell U.S. rights to Crohn's disease drug Entocort to Perrigo ($PRGO) for $380 million. Release

> Gilead ($GILD) has won a European green light for HIV regimen Genvoya. Release

> Merck ($MRK) has launched antibiotic Zerbaxa in the U.K. More

And Finally... AstraZeneca ($AZN) will sponsor a new health and science education element of U.K. soccer team Cambridge United's school sports program. More

Suggested Articles

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.

The FDA wants to know what, exactly, is in a drug name—and whether it influences how the product is perceived. So it's launching a study to find out.

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.